Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if their disease tests positive for EGFR activating mutations. Recently, several large, controlled, phase III studies have b...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Paz-Ares, Luis, Soulières, Denis, Moecks, Joachim, Bara, Ilze, Mok, Tony, Klughammer, Barbara
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2014
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4190899/
https://ncbi.nlm.nih.gov/pubmed/25100284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.12278
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk